Carmustine
Nitrosoureas
Sold as BICNU
- Drug class
- Nitrosoureas
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 4
- Products on record
- 19
- FDA reports (12 mo)
- 170
Overview
Carmustine is an active pharmaceutical ingredient in the Nitrosoureas group (L01AD). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 13 | May 15, 2026 |
| US United States | FDA | 3 | November 21, 2025 |
| CA Canada | Health Canada | 2 | June 27, 2025 |
| EU European Union | EMA | 1 | September 3, 2024 |
GBUnited Kingdom· MHRA
13 products
Uses
GLIADEL
Implant is indicated for the treatment of adult patients with newly- diagnosed high-grade malignant glioma as an adjunct to surgery and radiation. GLIADEL Implant is indicated as an adjunct to surgery for the treatment of adult patients with recurrent histologically proved glioblastoma multiforme and for whom surgical resection is indicated.
How to take
USUnited States· FDA
3 products
Uses
1 INDICATIONS AND USAGE Carmustine for injection, USP is indicated as palliative therapy as a single agent or in established combination therapy in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors.
Multiple myeloma in combination with prednisone. Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs. Carmustine for injection, USP is a nitrosourea indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors (1) Multiple myeloma-in combination with prednisone (1) Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs (1) Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs (1)
CACanada· Health Canada
2 products
Uses
BiCNU (carmustine ) is indicated as palliative therapy to surgery and radiotherapy as a single agent or in established combination therapy with other chemotherapeutic agents in the following: • Brain tumours - glioblastoma, medulloblastoma, astrocytoma and metastatic brain tumours.
• Multiple myeloma - in combination with glucocorticoid such as prednisone. • Hodgkin's disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.
• Non-Hodgkin's lymphomas - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. • Tumours of the Gastrointestinal tract.
• Malignant melanoma when used in combination with other antineoplastic drugs.
Pediatrics Pediatrics (<18 years of age):
EUEuropean Union· EMA
1 product
Uses
Carmustine is indicated in adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): - Brain tumours (glioblastoma, Brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases - Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease - Tumours of the gastrointestinal tract, - Malignant melanoma in combination with other antineoplastic medicinal products.
- as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma).
How to take
Drug interactions
Known interactions involving Carmustine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL316440030 · revised May 15, 2026
- [2]FDA DailyMed · 06a0322b-eb28-44… · revised November 18, 2025 [PDF]
- [3]Health Canada (DPD) · 00297763 · revised June 27, 2025
- [4]European Medicines Agency · EMEA/H/C/004326 · revised September 3, 2024
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.